GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LENZ Therapeutics Inc (NAS:LENZ) » Definitions » Minority Interest

LENZ (LENZ Therapeutics) Minority Interest : $0.00 Mil (As of Sep. 2024)


View and export this data going back to 2024. Start your Free Trial

What is LENZ Therapeutics Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

LENZ Therapeutics's minority interest for the quarter that ended in Sep. 2024 was $0.00 Mil.


LENZ Therapeutics Minority Interest Historical Data

The historical data trend for LENZ Therapeutics's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LENZ Therapeutics Minority Interest Chart

LENZ Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Minority Interest
- - -

LENZ Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

LENZ Therapeutics Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.


LENZ Therapeutics Business Description

Traded in Other Exchanges
N/A
Address
445 Marine View Avenue, STE No. 320, Del Mar, CA, USA, 92014
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.